Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorbald van Hall

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Nature Medicine|March 22, 2006
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variantsThorbald van Hall, Elisabeth Z Wolpert, Peter van Veelen, et al.
Science Immunology|May 19, 2023
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistanceMandy van Gulijk, Anneloes van Krimpen, Sjoerd Schetters, et al.
Journal for Immunotherapy of Cancer|March 10, 2022
Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin STom J Harryvan, Marten Visser, Linda de Bruin, et al.
Cell Reports|December 4, 2023
The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferentJim Middelburg, Soroush Ghaffari, Tom A W Schoufour, et al.
Journal for Immunotherapy of Cancer|July 22, 2020
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine modelSai Ping Lau, Nadine van Montfoort, Priscilla Kinderman, et al.
Nature Communications|May 28, 2025
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation studyMitchell Emmers, Marij J P Welters, Michelle V Dietz, et al.
Cancer Cell|October 2, 2020
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesFloris Dammeijer, Mandy van Gulijk, Evalyn E Mulder, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2018
A Restricted Role for FcγR in the Regulation of Adaptive ImmunityMarieke F Fransen, Hreinn Benonisson, Wendy W van Maren, et al.
Nature Immunology|December 15, 2010
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopesJan H Kessler, Selina Khan, Ulrike Seifert, et al.
Nature Biomedical Engineering|April 9, 2025
Site-directed multivalent conjugation of antibodies to ubiquitinated payloadsAngela F El Hebieshy, Zacharias Wijfjes, Camille M Le Gall, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Nature Medicine|March 22, 2006
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variantsThorbald van Hall, Elisabeth Z Wolpert, Peter van Veelen, et al.
Science Immunology|May 19, 2023
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistanceMandy van Gulijk, Anneloes van Krimpen, Sjoerd Schetters, et al.
Journal for Immunotherapy of Cancer|March 10, 2022
Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin STom J Harryvan, Marten Visser, Linda de Bruin, et al.
Cell Reports|December 4, 2023
The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferentJim Middelburg, Soroush Ghaffari, Tom A W Schoufour, et al.
Journal for Immunotherapy of Cancer|July 22, 2020
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine modelSai Ping Lau, Nadine van Montfoort, Priscilla Kinderman, et al.
Nature Communications|May 28, 2025
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation studyMitchell Emmers, Marij J P Welters, Michelle V Dietz, et al.
Cancer Cell|October 2, 2020
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesFloris Dammeijer, Mandy van Gulijk, Evalyn E Mulder, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 11, 2018
A Restricted Role for FcγR in the Regulation of Adaptive ImmunityMarieke F Fransen, Hreinn Benonisson, Wendy W van Maren, et al.
Nature Immunology|December 15, 2010
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopesJan H Kessler, Selina Khan, Ulrike Seifert, et al.
Nature Biomedical Engineering|April 9, 2025
Site-directed multivalent conjugation of antibodies to ubiquitinated payloadsAngela F El Hebieshy, Zacharias Wijfjes, Camille M Le Gall, et al.
Pageof 12